Biosimilar

Two adalimumab biosimilars, adalimumab-adaz and adalimumab-fkjp, demonstrated safety and effectiveness in patients with Crohn’s disease and ulcerative colitis, according to a study in PLOS One.

Lower-cost alternative drugs reduced total costs of care by approximately 5% while maintaining quality care among Medicare beneficiaries with cancer, according to study results presented at ASCO Quality Care Symposium.

The power imbalance between patients and providers can lead to medical gaslighting, which rheumatology patients have been experiencing for decades, according to experts.

The FDA approved bevacizumab-adcd for treatment of six cancer types, according to a press release from the biosimilar’s manufacturer.

In this episode, I share my preview of the hot topics for the upcoming AAO 2022 annual meeting, including my thoughts on ocular gene therapy and new treatments in the works.

Although biosimilar-to-biosimilar switching is not covered by health regulations or guidance, a systematic literature review suggests the practice is safe and effective, according to data published in BioDrugs.

The FDA approval of Alvotech’s Humira biosimilar is on hold until the company can address “certain deficiencies” the administration found during an inspection of a manufacturing facility, according to a press release.

As discussed in my Aug. 25 commentary, biologics are poised to assume a major role in the treatment of patients with potential or actual vision loss from congenital or acquired eye diseases and ocular degenerations.

Biosimilars are a promising option that might expand access to retinal therapies, reducing costs and improving real-world treatment outcomes as a result.

Biosimilars are coming and are here to stay.